WO1997011741A1 - Systeme d'administration iontophoretique de medicaments comprenant un dispositif reutilisable - Google Patents

Systeme d'administration iontophoretique de medicaments comprenant un dispositif reutilisable Download PDF

Info

Publication number
WO1997011741A1
WO1997011741A1 PCT/US1996/015513 US9615513W WO9711741A1 WO 1997011741 A1 WO1997011741 A1 WO 1997011741A1 US 9615513 W US9615513 W US 9615513W WO 9711741 A1 WO9711741 A1 WO 9711741A1
Authority
WO
WIPO (PCT)
Prior art keywords
controller
patch
drug
housing
patient
Prior art date
Application number
PCT/US1996/015513
Other languages
English (en)
Inventor
Ronald J. Flower
John E. Studer, Jr.
Original Assignee
Becton Dickinson And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson And Company filed Critical Becton Dickinson And Company
Priority to AU71190/96A priority Critical patent/AU7119096A/en
Publication of WO1997011741A1 publication Critical patent/WO1997011741A1/fr

Links

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R12/00—Structural associations of a plurality of mutually-insulated electrical connecting elements, specially adapted for printed circuits, e.g. printed circuit boards [PCB], flat or ribbon cables, or like generally planar structures, e.g. terminal strips, terminal blocks; Coupling devices specially adapted for printed circuits, flat or ribbon cables, or like generally planar structures; Terminals specially adapted for contact with, or insertion into, printed circuits, flat or ribbon cables, or like generally planar structures
    • H01R12/70—Coupling devices
    • H01R12/77—Coupling devices for flexible printed circuits, flat or ribbon cables or like structures
    • H01R12/778—Coupling parts carrying sockets, clips or analogous counter-contacts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R13/00—Details of coupling devices of the kinds covered by groups H01R12/70 or H01R24/00 - H01R33/00
    • H01R13/66—Structural association with built-in electrical component
    • H01R13/665—Structural association with built-in electrical component with built-in electronic circuit

Definitions

  • the present invention generally relates to iontophoretic systems for delivering drugs, medicines and the like to patients transdermally, i.e., through the skin, and more specifically relates to a reusable iontophoretic drug delivery device such as a controller attachable to a disposable drug- filled patch.
  • Transdermal drug delivery systems have, in recent years, become an increasingly important means of administering drugs and like therapeutic agent ⁇ .
  • Passive transdermal drug delivery systems
  • Active transdermal drug delivery systems
  • Passive systems deliver drug through the skin of the user unaided, an example of which would involve the application of a topical anesthetic to provide localized relief, as disclosed in U.S. Patent No. 3,814,095 (Lubens) .
  • Active systems deliver drug through the skin of the user using, for example, iontophoresis, which according to Stedman's Medical Dictionary, is defined as "the introduction into the tissues, by means of an electric current, of the ions of a chosen medicament.”
  • iontophoresis which according to Stedman's Medical Dictionary, is defined as "the introduction into the tissues, by means of an electric current, of the ions of a chosen medicament.”
  • Such systems offer advantages clearly not achievable by any other methods of administration, such as avoiding introduction of the drug through the gastro- intestinal tract or punctures in the skin to name a few.
  • Conventional iontophoretic devices such as those described in U.S. Patent Nos. 4,820,263 (Spevak et al. ) , 4,927,408 (Haak et al .
  • iontophoresis for delivering a drug or medicine transdermally through iontophoresis, basically consist of two electrodes, which are in contact with a portion of a patient's body.
  • a first electrode generally called the active electrode
  • the second electrode generally called the counter electrode, closes an electrical circuit that includes the first electrode and the patient's body.
  • the circuit includes a source of electrical energy, such as a battery.
  • the ionic substance to be driven into the body may be either positively charged or negatively charged.
  • the anode of the iontophoretic device becomes the active electrode and the cathode serves as the counter electrode to complete the circuit.
  • the cathode will be the active electrode and the anode will be the counter electrode.
  • this process is typically achieved by placing the ionic drug either in solution or in gel form on a carrier and placing the drug-containing carrier, for example, in the form of a drug-filled adhesive patch, into contact with the skin.
  • the pair of electrodes is placed in contact with the skin and with the carrier. Direct current is applied between the two electrodes. Under the influence of the electric field present, the drug molecules migrate through the skin. As current flows between the two electrodes placed at spaced apart locations on the skin, the current path carries the drug with it.
  • the adhesive patch may be applied to the desired portion of the patient's body and the controller attached to the patch.
  • the controller is as large as, or larger than, the patch. It also should be somehow secured in place on the patient so that the patient may remain mobile and carry both the patch and controller with him as he moves about.
  • Delivery of a drug to the patient iontophoretically may be accomplished either at a constant rate over a long period of time, or periodically at various intervals and in some situations, upon demand. As can be seen, it may be necessary for the dru -containing carrier to be maintained in contact with the patient's skin over a long period of time, either for continuous drug delivery, or to permit frequent interval delivery over a period of time.
  • One of the problems with an iontophoretic drug delivery device such as described above, especially one that is compact and portable to provide patient mobility, is how to attach the controller to the patient and yet be as unobtrusive as possible and comfortable for the patient where the system is to be applied for an extended period of time.
  • a side-by-side arrangement of patch and controller may occupy too much space on the patient's skin and limit the choices where the transdermal device may be attached to the patient. Also, the controller may then have to be fastened to the patient ' s skin by adhesive or a strap, for example, which may be uncomfortable to the user.
  • iontophoretic drug delivery device it may be necessary to use an iontophoretic drug delivery device over an extended period of time i.e., longer than 24 hours to delivery the necessary dosage of drug. As the length of delivery time increases, there is a need to develop small, unobtrusive iontophoretic delivery devices which can be easily worn on the skin under clothing.
  • the controller which may contain sophisticated electronics besides just a power source to control and monitor the delivery of drug to the patient, is repeatedly used while the patch is discarded after use and replaced with new patches.
  • the replaceable patches and controller should be so structured as to make it easy and convenient for the patient to replace used patches with new patches on the controller.
  • a iontophoretic drug delivery system including a controller which may be constructed in accordance with the present invention is particularly suited for reuse.
  • the controller for the system of the present invention preferably can be used with disposable patches to easily attach the system to the patient for delivering the drug, medicament or the like.
  • the controller of the present invention for use in combination with a drug-filled patch to form an operable iontophoresis drug delivery system includes a housing having an upper portion and a lower portion pivotably interconnected, with the upper portion and the lower portion being biased towards one another at a openable front end by biasing means, and the housing including electronic means for monitoring and controlling electrical current and electrical connection means positioned within the front end of the housing and electrically connected to the electronics so that when sufficient force is applied to the housing to overcome the biasing means, the upper portion and the lower portion are forced away from one another to open the front end and expose the electrical connection array whereby the electrical connection array may be interconnected with the drug-filled patch.
  • connection means is adapted to include an electrical array and also adapted so that upon opening the front end the patch may be inserted into the open front end in electrical contact with the connection means.
  • the open end of the housing includes a notch for keying the controller and the patch to insure proper interconnection and orientation.
  • the iontophoretic drug delivery system of the present invention includes a drug-filled patch removably attachable to the skin of a patient for iontophoretically delivery at least one drug to the patient, with the patch including conductive pad means for interconnection with the reusable controller, and a reusable controller removably, electrically connectable to the patch, the controller providing sufficient energy to the patch to drive the ionized medicament into the skin of the patient, with the controller including housing means having an upper portion and a lower portion pivotably interconnected, with the upper portion and the lower portion being biased towards one another at a openable front end by biasing means, and the housing including electronic means for monitoring and controlling electrical current, and with the front end of the controller housing means adapted to including electrical connection means positioned within the front end of the housing and electrically connected to the electronics so that when sufficient force is applied to the housing to overcome the biasing means, the upper portion and the lower portion are forced away from one another to open the front end and expose the electrical connection array whereby the electrical connection array may be interconnected with
  • Figure 1 is a perspective, schematic view of the controller of the present invention illustrating opening of the controller for interconnecting to the patch;
  • Figure 2 is a perspective view of the controller shown in Figure 1 illustrating interconnection of the controller and the patch;
  • Figure 3 is plan view of the patch for interconnection with the controller of the present invention.
  • Figure 4 is an perspective view of the controller having a member for attaching the patch thereto, whereby the patch having a corresponding member may be folded and the two members brought into contact with one another;
  • Figure 5 is a perspective bottom view of the controller illustrating attachment of the patch to the controller.
  • the iontophoretic drug deliver system of the present invention is illustrated in Figure 1-5, with the controller generally designated 10 and the patch generally designated 12.
  • the controller 10 of the present invention for use in the iontophoretic drug delivery system is electrically connectable to the patch 12 to form the operable system, with the patch being attachable to the skin of a patient 14.
  • the patch typically includes an active electrode assembly 16 and a counter electrode assembly 18. If a positively charged medicament is to be delivered to the skin
  • the medicament would be positioned in the active electrode assembly.
  • an third or adjunct electrode assembly is provided so that when delivering a local anesthetic such a Lidocaine, the local anesthetic may be delivered beneath the counter electrode as well as the active electrode as disclosed, for example, in co-pending Patent
  • 08/315,532 entitled “IONTOPHORESIS PATCH/CONTROLLER INTERCONNECTION USING A CONDUCTIVE ELASTOMER TO PROVIDE NOISE-FREE ELECTRICAL CONTACT BETWEEN PATCH AND CONTROLLER, " and Application Serial No. 08/315,533 entitled “IONTOPHORESIS ASSEMBLY INCLUDING CLEANABLE ELECTRICAL CONTACTS,” the disclosures of which are hereby incorporated by reference in their entirety.
  • the patch 12 is a generally planar flexible member and may be adhesively supported on the skin 14 of the patient ( Figure 5) .
  • the patch 12 includes an enlarged patch body 20 and an extending narrow tab 22.
  • the patch body 20 includes opposed planar surfaces 24 and 26, with the planar surface 24 disposed for skin contact and including a drug reservoir 28 typically in a gel form which contains at least one drug, medicament or like active agents (hereinafter collectively referred to simply as drugs) , preferably in an ionic form. While the drug reservoir 28 is shown, any other known iontophoretic drug reservoir structure for placing a medicament in contact with the skin in an iontophoretic patch may be employed, as disclosed for example in Patent Application Serial No.
  • Each of the electrode assemblies 16 and 18 are positioned to be in contact with the skin once the patch 12 is secured, as shown in Figure 5.
  • the positioning of the electrode assemblies 16 and 18 is such that an electrical current path is established between the electrode assemblies 16 and 18 through the skin of the patient 14.
  • a direct current source in combination with the electrode assemblies 16 and 18 and the patient ' s body 14 completes the circuit and generates an electric field across the body surface or skin to which the iontophoretic device is applied, with the drug reservoir 28 assumes the same charge as the ionized drug contained in the reservoir 28.
  • the drug contained in the drug reservoir 28 is transcutaneously delivered into the body of the patient by the process of iontophoresis.
  • the electrical current is supplied from the controller 10 to the electrode assemblies 16 and 18 on the patch via the electrical traces or leads 32 and 34 shown in Figure 3.
  • Each of the traces 32 and 34 may be one or more conductive paths extending from the electrode assemblies 16 and 18 to exposed conductive pads 36 ( Figure 3) positioned on a marginal edge of the patch tab 22.
  • the pads 36 are positioned for electrical connection to the controller 10, which provides a source of eiectrical current.
  • the particular construction of the patch 12 is not essential to the present invention, and may be formed of woven or non-woven textiles or polymers or may be any other construction well known in the art.
  • the electrode assemblies 16, 18, the electrical traces 32, 34 and the conductive pads be printed or otherwise formed on a polymeric substrate as disclosed, for example, in Patent Application Serial No. 08/012,168 entitled “ACTIVE DRUG DELIVERY DEVICE, ELECTRODE AND METHOD FOR MAKING SAME," the disclosure of which is hereby incorporated by reference in its entirety.
  • the controller 10 includes a controller housing 40 having an upper portion 42 and a lower portion 44 pivotably interconnected, with the portions being biased towards one another by a biasing means such as a spring 46.
  • the housing 40 has a general clothespin shape and includes an biasingly openable front end 48 which accommodates the tab 22 of the patch 12.
  • the housing 40 further accommodates a connection array 50 adjacent the electronics 52 contained within the housing 40 and schematically shown in phantom in Figure 2.
  • the connection array 50 and the electronics 52 are preferably mounted to a common printed circuit board (not shown) .
  • the connection array 50 may include plural electrical terminals in electrical connection with the electronics 52 and may be connectable to the pads 36 of the tab 20 extending from the patch 12.
  • connection array 50 is an electrical connection member having plural spaced-apart, exposed conductive surfaces separated by an insulating material.
  • any suitable electrical interconnection device may be employed in accordance with the present invention.
  • the controller 10 houses the electronics 52 that monitor and control the supply of electric current to the electrode assemblies 16 and 18 and the user interfaces.
  • the electrical components may include a source of electrical power such as a battery and additional electronic components, such as an application specific integrated circuit, a microprocessor, used to send a controlled electrical current to electrode assemblies 16 and 18.
  • additional electronic components such as an application specific integrated circuit, a microprocessor, used to send a controlled electrical current to electrode assemblies 16 and 18.
  • the particular electrode assemblies and the electronic array are not essential to the present invention, with the electrode assemblies including, for example, those disclosed in co-pending Patent Application entitled "IONTOPHORETIC DRUG DLEIVERY DEVICE HAVING AN IMPROVED CONTROLLER", filed September 28, 1995 (Attorney Docket No. P- 3173) , Application Serial No.
  • controller may be easily interconnected with the patch 12 under thumb actuation to an open position exposing the connection array 50 for electrical connection with the pads 36 of the tab 20.
  • the tab 20 is keyed to the housing 40.
  • the tab 22 includes an extending leg or like portion 38 on one side which is designed to fit in a corresponding notch 54 formed in at least one side of the front end 48 of the lower portion 42 of the housing 40.
  • the notch 54 and the leg 38 are of similar shape so as to provide keyed accommodation of the tab 20 and the leg 38.
  • the key structure included on both the housing front end 48 and the leg 38 insures proper orientation of the patch 12 and the controller 10 by preventing incorrect positioning of the patch 12 with respect to the controller 10.
  • both the front end 48 and the notch 54, and the corresponding tab 22 and the leg 38 have a generally L-shaped cross-section, however, any other mating shape which would prevent incorrect alignment may be employed.
  • the controller 10 and the patch 12 include attachment means for permitting the releasable support of the controller 10 on the patch 12 after interconnection between the pads 36 and the connective array 50 is established.
  • the surface 24 of patch 12, and the exposed upper portion 42 include cooperating fastening elements 56 and 58 thereon.
  • the cooperative fastening elements 56, 58 include conventional hook and loop fasteners of the type sold under the trademark VELCRO. Any other cooperating type fasteners may be employed to achieve the same objective.
  • One cooperating fastening element 56 is secured adhesively or otherwise to patch 12 on surface 24 while the other cooperating fastening member 58 is secured by adhesive or otherwise to the exposed surface of upper portion 42 of the housing 40.
  • attachment of the mating hook and loop fasteners 56 or 58 provide removable support for controller 10 on patch 12. It may be appreciated by those skilled in the art that the patch and controller may take any known form. The only requirement is that the patch be capable of being physically and electrically connected to the controller 10.
  • iontophoretic drug delivery system including the controller 10 and the patch 12, of the present invention, its operation and use is described below.
  • the controller 10 and patch 12 may be adhesively secured to the skin 14 of the patient, with surface 26 of patch 12 placed in intimate contact with the skin 14 so that the electrode assemblies 16 and 18, as well as the drug containing reservoir 28, are supported in intimate contact with the skin 14.
  • the reusable controller 10 of the present invention is electrically connected to patch 12.
  • the housing 40 is opened and the tab 22 of the patch 12 is inserted into the open front end 46 of the housing 40. Proper planar orientation is assured between the patch 12 and the controller 10 due to the key mateability between the notch 54 in the open front end 48 of the housing 40 and the extending leg 38 of the patch tab 22.
  • the controller 10 may be fastened or otherwise attached to the patch 12 so that it will be conveniently retained on the skin of the patient.
  • the controller may be flipped up so that the mating hook and loop fasteners 56 and 58 engage each other to removably fasten the controller 10 to the patch 12 as shown in Figure 5.
  • the controller 10 is comfortably retained on the skin of the patient during iontophoretic drug delivery.
  • the controller 10 and the patch 12 may be removed from the skin of the patient, and by separating the mating hook and loop fasteners 56 and 58, and pressing on the rear end of the housing 40, the controller 10 and the patch 12 may be separated. In this way, the controller may be disconnected and placed aside until the next administration of the drug is needed, when it can be reused with a new patch.
  • the patch 12 of the present invention contains Lidocaine (a local anesthetic) and Epinephrine or Adrenaline (vasoconstrictors) .
  • Lidocaine a local anesthetic
  • Epinephrine or Adrenaline vasoconstrictors
  • the device can be used for anesthetizing the applied area to minimize sensation from the insertion of a needle or the like.
  • other substances suitable for being applied to the area may be utilized which are well known to those skilled in the art.
  • Active agent drug, formulation, medication, medicament and active compound have been used herein to mean any ethical pharmaceutical compound or agent, such as therapeutic compounds, diagnostic agents, anesthetic agents and the like.
  • the device can be situated on the area of the patient to which the active agent is to be applied (the applied area) such as the skin and a v ⁇ ltage impressed across the electrode assemblies 16, 18 to cause electrical current to flow through the skin of the patient to drive or otherwise transport the drug preferably in the form of an ionic active agent into the skin and the tissue to be absorbed by the body of the patient.
  • the electric field lines are sufficiently long, however, so that the active agent is transported to the desired depth within the skin, and possibly to the vasculature, to provide the desired effect, e.g., anesthetic, therapeutic or diagnostic.
  • the device of the present invention can be applied to other areas of the body such as mucus membranes depending upon the desired therapy and drugs to be delivered.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention concerne un système d'administration iontophorétique de médicaments, lequel comprend une unité de commande réutilisable (10) pouvant être connectée de manière fiable à un timbre (12) contenant un médicament. Cette unité de commande (10) contrôle et commande l'alimentation en courant électrique du timbre (12) contenant le médicament lors de l'administration d'au moins un médicament. L'interconnexion électrique entre le timbre (12) et l'unité de commande (10) se fait en ouvrant la partie avant (48) de l'unité de commande (10) à l'aide du pouce, de sorte qu'une languette (22) dépassant du timbre (12) puisse être insérée dans ladite partie avant (48) ouverte qui est ensuite refermée avec la languette (22) à l'intérieur. La languette (22) du timbre (12) contenant le médicament comporte une patte (38) conçue pour rentrer dans une entaille correspondante (54) pratiquée dans la partie avant (48) de l'unité de commande (10), ceci de manière à offrir un logement de type clé pour la languette (22) et pour la patte (38). Cette structure de clé, qui se trouve tant sur la partie avant (48) du boîtier que sur la patte (38), permet d'éviter tout mauvais positionnement du timbre (12) par rapport à l'unité de commande (10). Dans un mode de réalisation préféré, la partie avant (48) et l'entaille (54), ainsi que la languette correspondante (22) et la patte (38), possèdent une section globalement en forme de L.
PCT/US1996/015513 1995-09-28 1996-09-27 Systeme d'administration iontophoretique de medicaments comprenant un dispositif reutilisable WO1997011741A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71190/96A AU7119096A (en) 1995-09-28 1996-09-27 Iontophoretic drug delivery system, including reusable device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53489795A 1995-09-28 1995-09-28
US08/534,897 1995-09-28

Publications (1)

Publication Number Publication Date
WO1997011741A1 true WO1997011741A1 (fr) 1997-04-03

Family

ID=24131972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/015513 WO1997011741A1 (fr) 1995-09-28 1996-09-27 Systeme d'administration iontophoretique de medicaments comprenant un dispositif reutilisable

Country Status (3)

Country Link
AU (1) AU7119096A (fr)
CA (1) CA2233197A1 (fr)
WO (1) WO1997011741A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1106204A1 (fr) * 1999-12-09 2001-06-13 Iomed, Inc. Système de connection pour un appareil d'ionophorèse comprenant une bande
EP1106203A1 (fr) * 1999-12-09 2001-06-13 Iomed, Inc. Système de connection pour un appareil d'ionophorèse
US9555226B2 (en) 2003-10-27 2017-01-31 Chrono Therapeutics Inc. Transdermal drug delivery method and system
US9669199B2 (en) 2004-09-13 2017-06-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
US10653686B2 (en) 2011-07-06 2020-05-19 Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919156A (en) 1996-09-27 1999-07-06 Becton, Dickinson And Company Iontophoretic drug delivery system, including unit for dispensing patches

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714436A (en) * 1986-12-15 1987-12-22 John Fluke Mfg. Co., Inc. Test clip with grounding adaptor for cable connector
WO1994028965A1 (fr) * 1993-06-08 1994-12-22 Becton Dickinson And Company Systeme de ionophorese portable
EP0642808A1 (fr) * 1993-09-10 1995-03-15 Asulab S.A. Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse
WO1996010442A1 (fr) * 1994-09-30 1996-04-11 Becton Dickinson And Company Systeme ameliore pour l'administration d'un medicament par ionophorese

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714436A (en) * 1986-12-15 1987-12-22 John Fluke Mfg. Co., Inc. Test clip with grounding adaptor for cable connector
WO1994028965A1 (fr) * 1993-06-08 1994-12-22 Becton Dickinson And Company Systeme de ionophorese portable
EP0642808A1 (fr) * 1993-09-10 1995-03-15 Asulab S.A. Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse
WO1996010442A1 (fr) * 1994-09-30 1996-04-11 Becton Dickinson And Company Systeme ameliore pour l'administration d'un medicament par ionophorese

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1106203A1 (fr) * 1999-12-09 2001-06-13 Iomed, Inc. Système de connection pour un appareil d'ionophorèse
EP2030648A1 (fr) * 1999-12-09 2009-03-04 Iomed, Inc. Système de connexion pour un dispositif d'administration de médicament iontophorétique
EP1106204A1 (fr) * 1999-12-09 2001-06-13 Iomed, Inc. Système de connection pour un appareil d'ionophorèse comprenant une bande
US10716764B2 (en) 2003-10-27 2020-07-21 Morningside Venture Investments Limited Transdermal drug delivery method and system
US9555226B2 (en) 2003-10-27 2017-01-31 Chrono Therapeutics Inc. Transdermal drug delivery method and system
US9555227B2 (en) 2004-09-13 2017-01-31 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
US9669199B2 (en) 2004-09-13 2017-06-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US11471424B2 (en) 2004-09-13 2022-10-18 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US10258738B2 (en) 2004-09-13 2019-04-16 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US10258778B2 (en) 2004-09-13 2019-04-16 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US10653686B2 (en) 2011-07-06 2020-05-19 Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
US10232156B2 (en) 2015-01-28 2019-03-19 Chrono Therapeutics Inc. Drug delivery methods and systems
US11400266B2 (en) 2015-01-28 2022-08-02 Morningside Venture Investments Limited Drug delivery methods and systems
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems

Also Published As

Publication number Publication date
CA2233197A1 (fr) 1997-04-03
AU7119096A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
US5830175A (en) Iontophoretic drug delivery system, including disposable patch
US5498235A (en) Iontophoresis assembly including patch/controller attachment
US5879322A (en) Self-contained transdermal drug delivery device
JP2802170B2 (ja) 携帯用のイオン電気導入装置
US5876368A (en) Iontophoretic drug delivery device having improved controller
US9956403B2 (en) Active transdermal medicament patch and circuit board for same
US5895369A (en) Iontophoresis patch/controller interconnection using a conductive elastomer to provide noise-free electrical contact between patch and controller
US5645526A (en) Apparatus and method for ensuring compatibility of a reusable iontophoretic controller with an iontophoretic patch
US5795321A (en) Iontophoretic drug delivery system, including removable controller
US5693024A (en) Iontophoretic drug delivery system, including method for determining hydration of patch
US5087241A (en) Iontophoresis electrode with reservoir and injection site
US20080214985A1 (en) Active transdermal medicament patch
JP2005185860A (ja) 改良された制御器及びパッチを有するイオン導入ドラッグ供給装置
US5919156A (en) Iontophoretic drug delivery system, including unit for dispensing patches
EP0934097B1 (fr) Systeme d'apport de medicament par ionophorese et procede de mise en oeuvre associe
WO1997011741A1 (fr) Systeme d'administration iontophoretique de medicaments comprenant un dispositif reutilisable
JPH11505158A (ja) 再使用可能なコントローラを有する電気輸送装置
WO1996010440A9 (fr) Dispositif d'administration d'un medicament par ionophorese, ayant un timbre et un systeme de commande ameliores
CA2201378A1 (fr) Systeme d'administration d'un medicament par ionophorese, comprenant un timbre a usage unique et un dispositif de commande amovible, reutilisable
WO1996010441A9 (fr) Systeme d'administration d'un medicament par ionophorese, comprenant un timbre a usage unique et un dispositif de commande amovible, reutilisable
WO2009091372A1 (fr) Timbre transdermique de médicament actif

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2233197

Country of ref document: CA

Ref country code: CA

Ref document number: 2233197

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1996932346

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996932346

Country of ref document: EP

122 Ep: pct application non-entry in european phase